The Role of Liquid Biopsy in Neuroblastoma: A Scoping Review

jpedsurg.org

Neuroblastoma (NBL), is the most common, non-CNS solid tumor of childhood. This disease presents with unique biological and clinical challenges necessitating accurate diagnosis, prognosis assessment, treatment, and vigilant monitoring. Liquid biopsy is an upcoming, innovative, and non-invasive diagnostic modality. It has the potential to detect tumors and perform therapeutic monitoring through the analysis of circulating biomarkers in blood, urine, saliva, and other bodily fluids.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Aug 2024 · 1 min read

In brief

This scoping review examines liquid biopsy as a non-invasive diagnostic tool for neuroblastoma, the most common extracranial solid tumor in children. The review explores how circulating biomarkers in bodily fluids can enhance tumor detection, prognostic assessment, and therapeutic monitoring in this challenging pediatric malignancy.

Neuroblastoma is the most common non-CNS solid tumor in children, requiring precise diagnosis and monitoring strategies.
Liquid biopsy offers a non-invasive alternative to tissue biopsy for detecting circulating tumor biomarkers.
Multiple bodily fluids (blood, urine, saliva) can be analyzed for neuroblastoma biomarkers via liquid biopsy.
Liquid biopsy shows promise for both initial tumor detection and ongoing therapeutic response monitoring in neuroblastoma.

Written by the GCMD Library team from the article.

Read it at the source ↗